Singapore says Nuvaxovid COVID vaccine won’t be available under NVP as of Jan. 1

The Singapore Ministry of Health stated in a notice posted to its website: “From 1 January 2024, the Novavax/Nuvaxovid COVID-19 vaccine will no longer be available under the National Vaccination Programme, NVP, as the existing formulation of the vaccine, which is based on the original COVID-19 strain, is no longer supplied by the manufacturer, and Singapore’s existing stock will expire on 31 December 2023. Novavax is in the process of filing for regulatory approval for its updated COVID-19 XBB.1.5 vaccine formulation. Further updates will be provided when Novavax has successfully filed for regulatory approval.”